IPSEN (IPN.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:IPN - FR0010259150 - Common Stock
IPN.PA Key Statistics, Chart & Performance
The current stock price of IPN.PA is 136 EUR. In the past month the price increased by 13.9%. In the past year, price increased by 13.9%.
IPN.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA is one of the better performing stocks in the market, outperforming 75.07% of all stocks.
IPN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA. While IPN.PA has a great health rating, its profitability is only average at the moment.
IPN.PA Financial Highlights
Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 10.27. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.92% | ||
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.2 |
IPN.PA Forecast & Estimates
18 analysts have analysed IPN.PA and the average price target is 131.03 EUR. This implies a price decrease of -3.65% is expected in the next year compared to the current price of 136.
For the next year, analysts expect an EPS growth of 10.08% and a revenue growth 8.8% for IPN.PA
IPN.PA Ownership
About IPN.PA
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Info
IPSEN
65 Quai Georges Gorse
Boulogne-Billancourt ILE-DE-FRANCE FR
Employees: 5358
Phone: 33158335000
IPSEN / IPN.PA FAQ
What does IPN do?
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
What is the stock price of IPSEN today?
The current stock price of IPN.PA is 136 EUR. The price increased by 2.41% in the last trading session.
What is the dividend status of IPSEN?
IPSEN (IPN.PA) has a dividend yield of 1.03%. The yearly dividend amount is currently 1.2.
How is the ChartMill rating for IPSEN?
IPN.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What sector and industry does IPSEN belong to?
IPSEN (IPN.PA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does IPSEN have?
IPSEN (IPN.PA) currently has 5358 employees.
What is the market capitalization of IPN stock?
IPSEN (IPN.PA) has a market capitalization of 11.40B EUR. This makes IPN.PA a Large Cap stock.